Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Meiji

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Meiji's Japan sales performance.

Roche’s Tamiflu successor hits the mark in complicated flu

Roche’s Tamiflu successor hits the mark in complicated flu is already on the market in Japan, where its originator Shionogi won approval earlier this year as Xofluza.

The NHS at 70: celebrations, renewed reforms and difficult choices

The NHS at 70: celebrations, renewed reforms and difficult choices This still leaves it in line with an unweighted EU-15 average of 9.8% of national income, but far behind countries such as the US (16.9%), Japan (11.2%),

Complete Medical Communications (CMC)

Four new global offices were established: Japan, Pennsylvania, Manchester and Glasgow, thereby providing a strengthened base on which to build in 2018.

Daily Brief: Dementia Fund hits $350m mark, hard Brexit could cost £100bn in trade and troublesome results for Pfizer’s Ibrance

Daily Brief: Dementia Fund hits $350m mark, hard Brexit could cost £100bn in trade and troublesome results for Pfizer’s Ibrance line. Business leaders from the US, Canada, Japan and India issued a joint statement yesterday, which said that international businesses who are “heavily invested” in both the EU and the UK ... Pfizer, MSD, Amgen and AbbVie- signed the statement

The year of the blockbuster

The year of the blockbuster The therapy was filed in Japan in March and an EU filing (February)   is also pending. ... just as the Drugs to Watch report was released; EU and Japan approvals also occurred that month.

[ Previous 5 results ] 10 11 12 13 14 15 16 17 18 19 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

My MS journey: one patient's search for innovation
David Lazarus charts his journey from initial MS diagnosis in 1990 to his experience participating in innovative clinical trials, along with his advice for other patients....
Biotech profile: Tom Evans, CEO, Vaccitech.
Can UK company be first to develop a universal flu vaccine?...
The social dilemma: is it time for pharma to join the party?
Chris Ross explores why social media still isn’t trending for pharma, and how it can join in the fun...

Infographics